Skip to content

Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)

Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01078051
Enrollment
840
Registered
2010-03-02
Start date
2010-03-22
Completion date
2019-07-22
Last updated
2019-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

chronic total occlusion, stent, medical therapy

Brief summary

The purpose of this study is to compare the safety and effectiveness of drug-eluting stent implantation compared to optimal medical treatment in patients with chronic total occlusion.

Detailed description

Prospective, two arms, randomized multi-center trial in Asian-pacific region. Following angiography, patients with chronic total occlusion (more than 3 months) have documented myocardial ischemia or symptoms of angina, and eligible for stenting without any exclusion criteria will be randomized 1:1 to: a) drug-eluting stent vs. b) optimal medical treatment. All patients will be followed for at least 3 year. The subjects with chronic total occlusion but failed to random for any reason, they will be enrolled in registry group. The random design was closed at the date of 22 July 2019 however already randomized subjects and subjects from registry design continue 10 years follow-up on IRIS-CTO registry.

Interventions

PROCEDURECypher, xience, Endeavor, Taxus

all species of drug-eluting stent implantation

DRUGoptimal medical therapy

optimal medical therapy

Sponsors

CardioVascular Research Foundation, Korea
CollaboratorOTHER
Seung-Jung Park
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Clinical 1. Patients with angina or silent ischemia and documented ischemia 2. Patients who are eligible for intracoronary stenting 3. Age \> 18 years Angiographic 1. De novo lesion CTO 2. Reference vessel size 2.5 mm by visual estimation 3. At least one CTO lesions located in proximal or mid epicardial coronary artery. (If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery) CTO definition: TIMI flow 0 and estimated duration over 3 months The duration of the occlusion was determined by the interval from the last episode of acute coronary syndrome, or In patients without a history of acute coronary syndrome, from the first episode of effort angina consistent with the location of the occlusion 1. Angiographically defined total occlusion over 3 months 2. If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)

Exclusion criteria

1. History of bleeding diathesis or coagulopathy 2. Pregnant state 3. Three vessel CTO 4. Known hypersensitivity or contra-indication to contrast agent and heparin 5. ST-elevation acute myocardial infarction requiring primary stenting 6. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels 4) Distal epicardial coronary artery CTO lesions 7. Hematological disease 8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation 3 times normal 9. Renal dysfunction, creatinine more than 2.0 10. Contraindication to aspirin, clopidogrel or other commercial antiplatelet agent 11. Left ventricular ejection fraction 12. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. 13. Non-cardiac co-morbid conditions are present with limited life expectancy or that may result in protocol non-compliance (per site investigator's medical judgment).

Design outcomes

Primary

MeasureTime frameDescription
Composite outcomes of all cause death, myocardial infarction, stroke, and any revascularization for 3 years after randomizationat 3 yearsat the median of 3 years

Secondary

MeasureTime frame
All Death (Cardiac death)at 3 years & 5 years
Angina class; Quality of life, clinical outcomes at 5 yearsat 3 years & 5 years
Myocardial infarction, stroke,any revascularization, CTO-vessel related revascularization, hospitalization due to acute coronary syndrome, left ventricular ejection fractionat 3 years & 5 years

Countries

India, Indonesia, South Korea, Taiwan, Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 9, 2026